The onset of anemia is a confounding factor that will affect the majority of patients with lung cancer. In an attempt to manage or prevent anemia in this population, three trials have incorporated erythropoietin in the treatment schedules. The results of erythropoietin use for cancer patients with anemia have been encouraging.
Get full access to this article
View all access options for this article.
References
1.
AbelsR.I.. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer.Semin Oncol.1992; 19(3 suppl 8): 29–35.
2.
HenryD.H., AbelsR.I.. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of a double-blind and open-label follow-up studies.Semin Oncol.1994; 21(2 suppl 3): 21–28.
3.
GlaspyJ., BukowskiR., SteinbergD.. Impact of therapy with epoietin alpha on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice.J Clin Oncol.1997; 15: 1218–1234.
4.
CrawfordJ., OzerH., StollerR.. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer.N Engl J Med.1991; 315: 164–170.
5.
CrawfordJ., BlackwellS., ShoemakerD.. Prevention of chemotherapy-related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support.Lung Cancer.1997; 18(suppl 1): 205.
